Fibrin clot properties and cardiovascular disease

Vascular Disease Prevention

Volumn 3, Issue 2, 2006, Pages 99-106

  Undas, Anetta ^a   Zeglin, Magdalena ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Cardiovascular disease; Clot; Fibrin; Genetic polymorphism; Risk factor; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BIGUANIDE; BLOOD CLOTTING FACTOR 13; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FIBRIN; FIBRINOGEN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; QUINAPRIL; SIMVASTATIN; SULFONYLUREA DERIVATIVE; THROMBIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG MECHANISM; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; FIBRIN CLOT; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN POLYMORPHISM; REVIEW; SMOKING; UNSTABLE ANGINA PECTORIS;

EID: 33646583539     PISSN: 15672700     EISSN: None     Source Type: Journal    
DOI: 10.2174/156727006776819369     Document Type: Review

References (82)

1. Blombäck B. Fibrinogen and fibrin- proteins with complex roles in haemostasis and thrombosis. Thromb Res 1996; 83: 1-75.
2. Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann NY Acad Sci 2001; 936: 11-30.
3. Brummel KE, Butenas S, Mann KG. An integrated study of fibrinogen during blood coagulation. J Biol Chem 1999; 232: 22862-70.
4. Meh DA, Siebenlist KR, Brennen SO, Holyst T, Mosesson MW. The amino acid sequence in fibrin responsible for high affinity thrombin binding. Thromb Haemost 2001; 85: 470-4.
5. Cooper AV, Standeven KF, Ariens RA. Fibrinogen gamma-chain splice variant gamma' alters fibrin formation and structure. Blood 2003; 102: 535-40.
6. Lovely RS, Falls LA, Mondhiry AI, et al. Association of gamma/gamma' fibrinogen levels and coronary artery disease. Thromb Haemost 2002; 88: 26-31.
7. Muszbek L, Yee LC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res 1999; 94: 271-305.
8. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129: 307-21.
9. Blombäck B, Carlsson K, Hessel B, Liljeborg A, Procyk R, Aslund N. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997: 96-110.
10. Nair CH, Azhar A, Dhall DP. Studies of fibrin network structure in human plasma. I.: methods for clinical application. Thromb Res 1991; 64: 455-476.
11. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005; 27: 81-90.
12. Carr ME. Fibrin formed in plasma is composed of fibers more massive han those formed from purified fibrinogen. Thromb Haemost 1988; 59: 535-539.
13. Blomback B, Carlsson K, Fatah K, Hrssel B, Procyk R. Fibrin in human plasma: gel architecture governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-38.
14. Collet JP, Park D, Lesty C, et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-61.
15. Mills JD, Ariens RA, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106: 1938-42.
16. Fatah K, Hamsten A, Blomback B, Blomback M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins, and coronary atherosclerosis. Thromb Hemost 1992; 68: 130-5.
17. Fatah K, Silveira A, Tornval P, et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76: 535-40.
18. Scott EM, Ariens RA, Grant PJ. Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 1558-66.
19. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Hemost 2003; 89: 601-9.
20. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principle results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
21. Collet JP, Soria J, Mirshahi M, et al. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood 1993; 82: 2462-9.
22. Green FR. Fibrinogen polymorphisms and atherothrombotic disease. Ann N Y Acad Sci 2001; 936: 549-59.
23. Iacoviello L, Vischetti M, Zito F, Benedetta DM. Genes encoding fibrinogen and cardiovascular risk. Hypertension 2001; 38: 1199-203.
24. Grant PJ. The genetics of atherothrombotic disorders: a clinician's view. J Thromb Haemost 2003; 1: 1381-90.
25. Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene- environment interactions may modulate vascular risk. Lancet 2003; 361: 1424-31.
26. Maghzal GJ, Brennen SO, George PM. Fibrinogen B beta polymorphism do not directly contribute to an altered in vitro clot structure in humans. Thomb Haemost 2003; 90: 1021-8.
27. Henschen-Edman AH. Fibrinogen non- inherited heterogeneity and its relationship to function in health and disease. Ann N Y Acad Sci 2001; 936: 580-93.
28. Behague I, Poirier O, Nicaud V, et al. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen level and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur I'Infarctus du Myocarde. Circulation 1996; 93: 440-9.
29. Carter AM, Catto AJ, Bamford JM, Grant PJ. Gender- specific associations of the fibrinogen B beta448 polymorphism, fibrinogen levels and acute cerebrovascular disease. Arterioscler Thromb Vasc Biol 1997; 17: 589-94.
30. Standeven KF, Grant PJ, Carter AM, et al. Functional analysis of the fibrinogen Aa Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 2003; 107: 2326-30.
31. Carter AM, Catto AJ, Grant PJ. Association of alpha-fibrinogen Thr312Ala polymorphism with post-stroke mortality in subjects with atrial fibrillation. Circulation 2001; 99: 2423-6.
32. Ariens RA, Lai TS, Weisel JW, Greenberg CS, Grant PJ. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 2002; 100: 743-54.
33. Ariens RA, Philippou H, Nagaswami C, et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and effects cross- linked fibrin structure. Blood 2000; 96: 988-95.
34. Wartiovaara U, Mikkola H, Szôke G, et al. Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A. Thromb Haemost 2000; 84: 595-600.
35. Schroeder V, Chatterjee T, Kohler HP. Influence of blood coagulation factor XIII and FXIII Val34Leu on plasma clot formation measured by thromboelastography. Thromb Res 2001; 104: 467-74.
36. Kobbervig C, Williams E. FXIII polymorphisms, fibrin clot structure and thrombotic risk. Biophys Chem 2004; 112: 223-8.
37. Kohler HP, Stickland MH, Ossei- Gernig N, et al. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8-13.
38. Humphries SE, Lane A, Dawson S, Green FR. The study of gene-environment interactions that influence thrombosis and fibrinolysis. Genetic variation at the loci for factor VII and plasminogen activator inhibitor-1. Arch Pathol Lab Med 1992; 116: 1322-9.
39. Zhan M, Zhou Y, Han ZC. No association of plasminogen activator inhibitor- 1 promoter 4G/5G polymorphism with inhibitor level during basal transcription in vitro. Int J Hematol 2004; 79: 400-4.
40. Iacoviello L, Burzotta F, Di Castelnuovo A, et al. The 4G/5G polymorphism of PAI- I promoter gene and a risk of myocardial infarction: a meta- analysis. Thromb Haemost 1998; 80: 1029-30.
41. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham Study. JAMA 1979; 24: 2035-8.
42. Dunn EL, Ariens RA. Fibrinogen and fibrin clot structure in diabetes. Herz 2004; 29: 470-9.
43. Jorneskog G, Egberg N, Fagrell B, et al. Altered properties of fibrin gel structure in patients with IDDM. Diabetologia 1996; 39: 1519-23.
44. Dunn E, Ariens RAS, Grant PJ. The influence of type 2 diabetes on clot structure and function. Diabetologia 2005; 48: 1198-206.
45. Hammer MR, John PN, Flynn MD, Bellingham AJ, Leslie RD. Glycated fibrinogen: a new index of short-term diabetic control. Ann Clin Biochem 1989; 26: 58-62.
46. Jorneskog G, Hansson LO, Wallen NH, Yungen M, Blomback M. Increased plasma fibrin gel porosity in patients with Type I diabetes during continuous subcutaneous insulin infusion. J Thromb Haemost 2003; 1: 1195-201.
47. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
48. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol Clin 2003; 21: 315-325.
49. Speidl WS, Zeiner A, Nikfardjam M, et al. An increase in Creactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion. J Am Coll Cardiol 2005; 45: 30-4.
50. Christiansen MS, Hommel E, Magid E, Feldt-Rasmussen B. Orosomucoid in urine is a powerful predictor of a cardiovascular mortality in normoalbuminuric patients with type 2 diabetes at five years of follow-up. Diabetologia 2005; 48: 386-93.
51. Celinska-Lowenhoff M, Lowenhoff T, Undas A, Szczeklik A. Drug-induced changes in fibrin clot permeability in patients with coronary artery disease. J Thromb Haemost 2005; 3 (suppl. 1): P0779.
52. Shats-Tseytlina EA, Nair CH, Dhall DP. Complement activation: a new participant in the modulation of fibrin gel characteristics and the progression of atherosclerosis. Blood Coagul Fibrinolysis 1994; 5: 529-35.
53. Mutanen M, Freese R. Fats, lipids and blood coagulation. Curr Opin Lipidol 2001; 12: 25-9.
54. Mussoni L, Mannucci L, Sirtori M, et al. Hypertriglyceridemia and regulation fibrinolytic activity. Arterioscler Thromb 1992; 12: 19-27.
55. Iso H, Shimamoto T, Sato S, et al. Passive smoking and plasma fibrinogen concentrations. Am J Epidemiol 1996; 144: 1511- 4.
56. Cesari M, Rossi GP, Sticchi D, Pessina AC. Is homocysteine important as a risk factor for coronary artery disease? Nutr Metab Cardiovasc Dis 2005; 15: 140-7.
57. Sauls DL, Wolberg AS, Hoffman M. Elevated plasma homocysteine leads to alteration in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. J Thromb Haemost 2003; 1: 300-6.
58. Lauricella AM, Quintana IL, Kordich LC. Effects of homocysteine thiol group on fibrin networks: another possible mechanism of harm. Thromb Res 2002; 107: 75-79.
59. Ebbesen LS, Christiansen K, Ingerslev J. Hyperhomocysteinemia due to folate deficiency is thrombogenic in rats. J Nutr 2003; 133: 2250-2255.
60. Jakubowski H. Protein homocysteinylation: Possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 1999; 13: 2277-83.
61. Sauls DL, Lockhart E, Hoffman M. Reaction of fibrinogen with homocysteine thiolactone renders the resulting fibrin clots resistant to lysis. J Thromb Haemost 2005; 3 (suppl. 1): OR130.
62. Antithrombotic Trialists Collaboration Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
63. Fatah K, Beving H, Albage A, Ivert I, Blomback M. Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient? Eur Heart J 1996; 17: 1362-6.
64. Williams S, Fatah K, Hjemdahl P, Blomback M. Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid. Eur Heart J 1998; 19: 1666-1672.
65. Williams S, Fatah K, Ivert T, Blombäck M. The effect of acetyl salicylic acid on fibrin gel lysis by tissue plasminogen activator. Blood Coagul Fibrinolysis 1995; 6: 718-25.
66. Bjornsson TD, Schneider DE, Berger H. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther 1989; 250: 154- 61.
67. Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: The CADET trial. J Thromb Haemost 2004; 2: 1934-40.
68. Undas A, Sydor WJ, Brummel K, et al. Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation 2003; 107: 17-20.
69. Undas A, Brzezinska-Kolarz B, Brummel-Ziedkins K, Musial J, Szczeklik A, Mann KG. Factor XIII Val34Leu polymorphism and γ-chain cross-linking at the site of microvascular injury in healthy and coumadin-treated subjects. J Thromb Haemost 2005; 3: 2015-2021.
70. Vaughan CJ, Gotto AM. Update on statins: 2003. Circulation 2004; 110: 886-92.
71. Celinska-Lowenhoff M, Undas A. Non-lipid effects of fibrates. Przegl Lek 2004; 61: 99-101.
72. Balk EM, Lau J, Goudas LC, et al. Effects of statins on non-lipid serum markers associated with cardiovascular disease: a systemic review. Ann Intern Med 2003; 139: 670-82.
73. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002; 18: 269-76.
74. Kock M, Gervois PP, Poulain P, et al. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood 1999; 93: 2991-8.
75. Okopien B, Cwalina L, Lebek M, et al. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia. Int J Clin Pharmacol Ther 2001; 39: 551-7.
76. Broijersen A, Hamsten A, Silveira A, et al. Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII. Thromb Haemost 1996; 76: 171-6.
77. Fanghanel G, Silva U, Sanches- Reyes L, et al. Effects of metformin on fibrinogen levels in obese patients with type 2 diabetes. Rev Invest Clin 1998; 50; 389-94.
78. Cefalu WT, Schneider DJ, Carlson HE, et al. Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects. Diabetes Care 2002; 25: 2123-8.
79. Yudkin JS, Panahloo A, Stehouwer C, et al. The influence of improved glycemic control with insulin and sulphonyloureas on acute phase and endothelial markers in Type II diabetic subjects. Diabetologia 2000; 43: 1099-106.
80. Standeven KF, Ariens RA, Whitaker P, et al. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 2002; 51: 189-97.
81. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003; 29: 6S44- 52.
82. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34). Lancet 1998; 352: 854-65.